The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …

Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies,
antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with …

The use of radiolabelled antibodies was proposed in 1970s for staging of malignant
tumours. Intensive research established chemistry for radiolabelling of proteins and …

The human epidermal growth factor receptor family (EGFR-family, other designations: HER
family, RTK Class I) is strongly linked to oncogenic transformation. Its members are …

Objective: GPVI (glycoprotein VI) is a key molecular player in collagen-induced platelet
signaling and aggregation. Recent evidence indicates that it also plays important role in …

Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins that can
be selected for binding to desirable molecular targets. High affinity and small size of …

Epithelial cell adhesion molecule (EpCAM) is overexpressed in 55%–75% of ovarian
carcinomas (OC). EpCAM might be used as a target for a treatment of disseminated OC …

Radionuclide molecular imaging is a promising tool that becomes increasingly important as
targeted cancer therapies are developed. To ensure an effective treatment, a molecular …

This review examines the evolution of the radionuclide diagnosis of HER2-positive breast
cancer using various compounds as a targeting module in clinical practice: from full-length …

Radionuclide molecular imaging of human epidermal growth factor receptor 2 (HER2) in
breast and gastroesophageal cancer might be used to stratify patients for HER2-targeted …